NEO PanTracer Pro
Use
The pan-solid tumor assay is designed to guide therapy selection and identify clinical trial options for patients with advanced stage solid tumors. It detects genomic alterations relevant to diagnosis, therapy selection, prognosis, and clinical trial options in solid tumors. The addition of IHC and ancillary testing provides comprehensive information for therapy selection beyond standard CGP testing, ideal for patients with newly diagnosed, recurrent, or progressive advanced cancer needing comprehensive clinical investigation.
Special Instructions
Diagnosis information provided will determine tumor type-directed IHC and ancillary testing. Refer to PanTracer Pro Testing by Cancer Type for the full list of associated add-ons by cancer diagnosis.
Limitations
Only blocks from the same procedure and the same tumor should be submitted together. Use a single block for large resections where tumor is abundant, or up to 4 blocks from procedures with smaller specimens. Decalcified samples are not accepted. For HRD assessment, ≥40% tumor is required.
New York Approved
Methodology
NGS (CGP)
Biomarkers
Result Turnaround Time
8-10 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Paraffin blocks
Storage Instructions
Use cold pack for transport, ensuring cold pack is not in direct contact with specimen.
Causes for Rejection
Decalcified samples are not accepted.